Jay Kranzler
Chairman at AVENUE THERAPEUTICS, INC.
Net worth: 409 $ as of 30/05/2024
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
David Jin | M | 34 | - | |
Glenn Cornett | M | - |
Pastorus, Inc.
Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | - |
Lindsay Rosenwald | M | 68 |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | 9 years |
Neil Herskowitz | M | 67 | 9 years | |
Michael Weiss | M | 58 |
Baergic Bio, Inc.
Baergic Bio, Inc. Pharmaceuticals: MajorHealth Technology Baergic Bio, Inc. develops therapeutic drugs for the treatment of central nervous system disorders. It offers oncology, rare diseases, and gene therapy. The company is headquartered in New York, NY. | 5 years |
Alexandra MacLean | M | 57 | 2 years | |
Sanjay Keswani | M | 54 |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | - |
Curtis Oltmans | M | 60 | 3 years | |
Michal Schwartz | M | - |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | 9 years |
Nathan Hevrony | M | 72 |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | 9 years |
Faith Charles | F | 62 | 2 years | |
David Ben-Ami | M | 63 |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | 7 years |
Eti Yoles | M | - |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | 8 years |
Brady Dougan | M | 64 |
Regenovation, Inc.
Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | - |
Jaclyn Jaffe | F | - | - | |
Yaki Enoch | M | - |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | - |
Ehud Barak | M | 81 |
ImmunoBrain Checkpoint Ltd.
ImmunoBrain Checkpoint Ltd. BiotechnologyHealth Technology ImmunoBrain Checkpoint Ltd. engages in the development of neuroprotective immune therapies for neurodegenerative diseases. The company was founded by Michal Schwartz and Nathan Hevrony in 2015 and is headquartered in Ness Ziona, Israel. | - |
Isaac Blech | M | 73 |
Regenovation, Inc.
Regenovation, Inc. Miscellaneous Commercial ServicesCommercial Services Regenovation, Inc. develops ways to regenerate human tissue. The company is headquartered in New York, NY. | - |
Srinivas Rao | M | - |
Pastorus, Inc.
Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | - |
Hannah Page Bell | F | - |
Pastorus, Inc.
Pastorus, Inc. Pharmaceuticals: GenericHealth Technology Pastorus, Inc. is a biotechnology company based in the United States that is focused on developing improved, patent-protected forms of oxytocin and other drugs to treat autism. Pastorus aims to address the particular need for drugs to treat autism, a disorder that affects over 3 million individuals in the US and tens of millions worldwide. The American company's core team of three physician-neuroscientists, each with over 20 years of industry experience, collaborate with successful experts in regulatory, clinical, manufacturing, and other domains. Recent research has demonstrated the potential to amplify oxytocin's favorable effects with a combination product, for which Pastorus has a pending patent application. The private company was founded by Jim Page and Glenn Cornett, with Glenn Cornett serving as CEO since incorporation. | - |
Scott Reines | M | 77 | 8 years | |
Michael Ryan | M | - | 6 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Xiao Qin Lu | M | 49 | 7 years | |
Sabrina Johnson | F | 57 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 12 years |
Joseph Vazzano | M | 40 | 5 years | |
Jaideep Gogtay | M | 58 | 3 years | |
Thomas G. Moore | M | 72 | 1 years | |
Elizabeth Ingram | F | 59 | 3 years | |
Nishant Saxena | M | 48 | - | |
Jeff Paley | M | 55 | 4 years | |
Jeffrey Meckler | M | 57 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 1 years |
Karin Eastham | F | 74 |
Cytel Corp.
| 5 years |
Akhtar Samad | M | 64 | 4 years | |
R. Gendreau | M | 68 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 30 years |
Amir Kalali | M | 58 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 7 years |
Tina Nova | M | 70 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | - |
Casey Pogodzinski | M | - |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 2 years |
Shawn DeFrees | M | 65 |
Cytel Corp.
| 8 years |
Ciara Kennedy | M | 52 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 5 years |
Jean-Pierre Millon | M | 73 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 6 years |
Michael J. Walsh | M | 64 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 2 years |
David Anderson | M | 71 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 2 years |
Denise L. Wheeler | F | 54 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | - |
Srinivas Rao | M | 55 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | - |
Perry B. Molinoff | M | 84 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 6 years |
Jack H. Vaughn | M | - |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 16 years |
Samuel D. Anderson | M | 89 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 9 years |
Michael Powell | M | 69 |
Cytel Corp.
| 3 years |
John N. Bonfiglio | M | 69 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 1 years |
David J. Horin | M | 56 | 2 years | |
Daniel Petree | M | 68 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 7 years |
Gary D. Tollefson | M | 72 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 3 years |
Jon W. McGarity | M | 82 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | - |
Roger L. Hawley | M | 71 |
Cypress Bioscience, Inc.
Cypress Bioscience, Inc. BiotechnologyHealth Technology Cypress Bioscience, Inc. develops drug therapies for Functional Somatic Syndromes, rheumatoid conditions that often cause sufferers chronic pain. The company provides medicine for Fibromyalgia Syndrome, a condition marked by painful stiffness, headaches and fatigue that affects approximately 5% of the world's population. The company was founded in 1981 and is located in San Diego, CA. | 3 years |
Wendy Johnson | F | 72 |
Cytel Corp.
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 48 | 87.27% |
Israel | 7 | 12.73% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jay Kranzler
- Personal Network